{"doi":"10.1016\/S0168-8510(02)00066-0","coreId":"92390","oai":"oai:eprints.lse.ac.uk:160","identifiers":["oai:eprints.lse.ac.uk:160","10.1016\/S0168-8510(02)00066-0"],"title":"Health economic evaluation in Japan: a case study of one aspect of health technology assessment","authors":["Oliver, Adam"],"enrichments":{"references":[{"id":789571,"title":"( 1996b) A case for the adoption of pharm a c o e c o n o m i c guidel i n e s in Japan.","authors":[],"date":null,"doi":null,"raw":null,"cites":null},{"id":17323880,"title":"A case for the adoption of pharmacoeconomic guidelines in Japan.","authors":[],"date":"1996","doi":"10.2165\/00019053-199610060-00003","raw":"Ikeda, S., Ikegami, N., Oliver, A. J. and Ikeda, M. (1996b) A case for the adoption of pharmacoeconomic guidelines in Japan. PharmacoEconomics, 10:6, 546-551.","cites":null},{"id":790346,"title":"A critic al review of cancer scr eeni n g program s in Japan.","authors":[],"date":"1994","doi":null,"raw":null,"cites":null},{"id":17323893,"title":"A critical review of cancer screening programs in Japan.","authors":[],"date":"1994","doi":"10.1017\/s0266462300006590","raw":"Oshima, A. (1994) A critical review of cancer screening programs in Japan. International Journal of Technology Assessment in Health Care 10:3, 346-358.","cites":null},{"id":789406,"title":"A review of phar m ac o e c o n o m i c studies in Japan (abstrac t C27). First Annual Interna t i o n a l Meetin g for the Associ a t i o n for Pharm a c o e c o n o m i c s and Outcom e s Resear c h , P h ilad e l p h i a ,","authors":[],"date":"1996","doi":null,"raw":null,"cites":null},{"id":17323879,"title":"A review of pharmacoeconomic studies","authors":[],"date":"1996","doi":"10.1016\/s0149-2918(96)80137-8","raw":"Ikeda, S., Noguchi, N., Oliver, A. (1996a) A review of pharmacoeconomic studies in Japan (abstract C27). First Annual International Meeting  for the Association for Pharmacoeconomics and Outcomes Research, Philadelphia, May 12.","cites":null},{"id":17323890,"title":"An analysis of pharmacoeconomic studies in Japan.","authors":[],"date":"1995","doi":null,"raw":"Moriga, M., Ikeda, S. and Reich, M. R. (1995) An analysis of pharmacoeconomic studies in Japan. Iryo Keizai Kenkyu 2, 71-81. NICE (2001) http:\/\/www.nice.nhs.uk Norwegian Medicines Control Authority (1999) Norwegian Guidelines for Pharmacoeconomic Analysis in Connection with Application for Reimbursement. Norwegian Medicines Control Authority (SLK), Oslo.","cites":null},{"id":17323874,"title":"Applicability of pharmacoeconomic studies to policy decision in Japan. Iryo to","authors":[],"date":"1998","doi":null,"raw":"Hamashima, C., Ikeda, S. and Yoshida, K. (1998) Applicability of pharmacoeconomic studies to policy decision in Japan. Iryo to Shakai 8:1, 11-24. [In Japanese] Hisashige, A. (1992) The contribution of medical technology to health improvement.","cites":null},{"id":787642,"title":"Commonwe a lth of Australia","authors":[],"date":"1995","doi":null,"raw":null,"cites":null},{"id":787902,"title":"Cultur e , confli c t , a nd cost: perspect i v e s on brain death","authors":[],"date":"1994","doi":null,"raw":null,"cites":null},{"id":17323873,"title":"Culture, conflict, and cost: perspectives on brain death in Japan.","authors":[],"date":"1994","doi":"10.1017\/s026646230000667x","raw":"Feldman, E. A. (1994) Culture, conflict, and cost: perspectives on brain death in Japan. International Journal of Technology Assessment in Health Care 10:3, 447-463.","cites":null},{"id":790114,"title":"Effect of Japanes e govern m e n t policy on hospit a l pharm a c e u t i c a l profi t lev e l s .","authors":[],"date":"1999","doi":null,"raw":null,"cites":null},{"id":17323892,"title":"Effect of Japanese government policy on hospital pharmaceutical profit levels.","authors":[],"date":"1999","doi":null,"raw":"Oliver, A. J., Ikegami, N. and Ikeda, S. (1999) Effect of Japanese government policy on hospital pharmaceutical profit levels. Journal of Health Services Research and Policy 4:1, 27-32.","cites":null},{"id":17323872,"title":"Guidelines for the Pharmaceutical Industry on Preparation of Submissions to the Pharmaceutical Benefits Advisory Committee: Including Submissions Involving Economic Analyses. Australian Government Printing Office,","authors":[],"date":"1995","doi":null,"raw":"Commonwealth of Australia (1995) Guidelines for the Pharmaceutical Industry on Preparation of Submissions to the Pharmaceutical Benefits Advisory Committee: Including Submissions Involving Economic Analyses. Australian Government Printing Office, Canberra.","cites":null},{"id":788156,"title":"Ha m a shi m a","authors":[],"date":"1998","doi":null,"raw":null,"cites":null},{"id":788896,"title":"Health c a r e tec hno l o g y assess m e n t and the challe n g e to pharm a c o e c o n o m i c s in Japan .","authors":[],"date":"1997","doi":null,"raw":null,"cites":null},{"id":789128,"title":"Health econom i c s of care for patie n t s with cance r and intr a c t a b l e disea s e in Japan .","authors":[],"date":"1998","doi":null,"raw":null,"cites":null},{"id":17323878,"title":"Health economics of care for patients with cancer and intractable disease in Japan.","authors":[],"date":"1998","doi":"10.1007\/s005200050205","raw":"Hisashige, A., Katayama, T. and Mikasa, H. (1998) Health economics of care for patients with cancer and intractable disease in Japan. Support Care Cancer 6, 503-510.","cites":null},{"id":789818,"title":"Health tec hnology development in Japan.","authors":[],"date":"1988","doi":null,"raw":null,"cites":null},{"id":17323881,"title":"Health technology development in Japan.","authors":[],"date":"1988","doi":null,"raw":"Ikegami, N. (1988) Health technology development in Japan. International Journal of Technology Assessment in Health Care 4, 239-254.","cites":null},{"id":17323877,"title":"Healthcare technology assessment and the challenge to pharmacoeconomics in Japan.","authors":[],"date":"1997","doi":"10.2165\/00019053-199711040-00003","raw":"Hisashige, A. (1997) Healthcare technology assessment and the challenge to pharmacoeconomics in Japan. Pharmacoeconomics 11:4, 319-333.","cites":null},{"id":790099,"title":"Japan\u2019 s aging popula t i o n : implic a t i o n s for heal t h care.","authors":[],"date":"1997","doi":null,"raw":null,"cites":null},{"id":17323891,"title":"Japan\u2019s aging population: implications for healthcare.","authors":[],"date":"1997","doi":"10.2165\/00019053-199711040-00002","raw":"Oliver, A. J., Ikegami, N. and Ikeda, S. (1997) Japan\u2019s aging population: implications for healthcare. Pharmacoeconomics 14:4, 306-318.","cites":null},{"id":17323886,"title":"Medical care in Japan.","authors":[],"date":"1995","doi":"10.1056\/nejm199511093331922","raw":"Ikegami, N. and Campbell, J. C. (1995) Medical care in Japan. New England Journal of Medicine 333:19, 1295-1299.","cites":null},{"id":17323887,"title":"Nihon no Iryou. Chuokoronsha,","authors":[],"date":"1996","doi":null,"raw":"Ikegami, N. and Campbell, J. C. (1996) Nihon no Iryou. Chuokoronsha, Tokyo. [In Japanese] Ikegami, N., Mitchell, W. and Penner-Hahn, J. (1994) Pharmaceutical prices, quantities and innovation: comparing Japan with the US. Pharmacoeconomics 6, 424-433.","cites":null},{"id":17323889,"title":"Ontario Guidelines for Economic Analysis of Pharmaceutical Products. Ministry of Health,","authors":[],"date":"1994","doi":null,"raw":"Ministry of Health (1994) Ontario Guidelines for Economic Analysis of Pharmaceutical Products. Ministry of Health, Toronto.","cites":null},{"id":17323885,"title":"Public long-term care insurance in Japan.","authors":[],"date":"1997","doi":"10.1001\/jama.278.16.1310","raw":"Ikegami, N. (1997) Public long-term care insurance in Japan. The Journal of the American Medical Association 278:16, 1310-1314.","cites":null},{"id":790585,"title":"Sicknes s Funds Counci l","authors":[],"date":"1999","doi":null,"raw":null,"cites":null},{"id":17323895,"title":"Sickness Funds Council","authors":[],"date":"1999","doi":null,"raw":"Sickness Funds Council (1999) Dutch Guidelines for Pharmacoeconomic Research. Ziekenfondsraad, Amstelveen.","cites":null},{"id":17323888,"title":"The cost-effectiveness of lifesaving interventions in Japan: do the variations found suggest irrational resource allocation?","authors":[],"date":"1999","doi":null,"raw":"Kishimoto, A. (1999) The cost-effectiveness of lifesaving interventions in Japan: do the variations found suggest irrational resource allocation? Proceedings of the Second International Workshop on Risk Evaluation and Management of Chemicals, Yokohama, January 29.","cites":null},{"id":17323883,"title":"The economics of health care in Japan.","authors":[],"date":"1992","doi":"10.1126\/science.1411572","raw":"Ikegami, N. (1992) The economics of health care in Japan. Science 258, 614-618.","cites":null},{"id":788598,"title":"The introducti o n and evaluat i o n of MRI","authors":[],"date":"1994","doi":null,"raw":null,"cites":null},{"id":17323876,"title":"The introduction and evaluation of MRI","authors":[],"date":"1994","doi":"10.1017\/s0266462300006632","raw":"Hisashige, A. (1994) The introduction and evaluation of MRI in Japan. International Journal of Technology Assessment in Health Care 10:3, 392-405.","cites":null},{"id":788369,"title":"The Japanese health care syste m at the cross r o a d s : healt h care expend i t u r e s , techno l o g y util iz a t i o n and gaps in health care techno l o g y assess m e n t .","authors":[],"date":"1993","doi":null,"raw":null,"cites":null},{"id":17323875,"title":"The Japanese health care system at the crossroads: health care expenditures, technology utilization and gaps in health care technology assessment.","authors":[],"date":"1993","doi":null,"raw":"Hisashige, A. (1993) The Japanese health care system at the crossroads: health care expenditures, technology utilization and gaps in health care technology assessment. Journal of Japanese Association of Radiological Technologist 40, 50-64.","cites":null}],"documentType":{"type":0.7777777778}},"contributors":[],"datePublished":"2003","abstract":"There is a burgeoning literature in health economic evaluation, with this form of analysis becoming increasingly influential at the health policy making level in a number of countries. However, a search of the literature reveals that in Japan, the world's second largest health care market, very little health economic evaluation has been undertaken. The main reason for the lack of interest in economic evaluation is that the fee-for-service and strict price regulation that characterises the system of health care financing in Japan is not conducive to this form of analysis. Moreover, the government and many researchers are satisfied that the current organisation of health care has given long life and low infant mortality at low cost. Even if it is accepted that low health care costs and good health prevail in Japan, slower economic growth rates, an ageing population and the development of new medical technologies will place increasing pressure on health care resources and will necessitate a more rational use of these resources. Good economic evaluation, by weighing benefits against costs, has an important role to play","downloadUrl":"https:\/\/core.ac.uk\/download\/pdf\/92390.pdf","fullTextIdentifier":"http:\/\/eprints.lse.ac.uk\/160\/1\/Health_economic_evaluation_in_Japan.pdf","pdfHashValue":"45d5bc23be4a9ae65e081ba8587c2954098d9a77","publisher":null,"rawRecordXml":"<record><header><identifier>\n    \n    \n      oai:eprints.lse.ac.uk:160<\/identifier><datestamp>\n      2012-08-15T08:43:43Z<\/datestamp><setSpec>\n      74797065733D434F4C4C53:4C53455F435F454F<\/setSpec><\/header><metadata><oai_dc:dc xmlns:oai_dc=\"http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc\/\" xmlns:dc=\"http:\/\/purl.org\/dc\/elements\/1.1\/\" xmlns:xsi=\"http:\/\/www.w3.org\/2001\/XMLSchema-instance\" xsi:schemaLocation=\"http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc\/ http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc.xsd\" ><dc:relation>\n    \n      \n        http:\/\/eprints.lse.ac.uk\/160\/<\/dc:relation><dc:title>\n        Health economic evaluation in Japan: a case study of one aspect of health technology assessment<\/dc:title><dc:creator>\n        Oliver, Adam<\/dc:creator><dc:subject>\n        HB Economic Theory<\/dc:subject><dc:description>\n        There is a burgeoning literature in health economic evaluation, with this form of analysis becoming increasingly influential at the health policy making level in a number of countries. However, a search of the literature reveals that in Japan, the world's second largest health care market, very little health economic evaluation has been undertaken. The main reason for the lack of interest in economic evaluation is that the fee-for-service and strict price regulation that characterises the system of health care financing in Japan is not conducive to this form of analysis. Moreover, the government and many researchers are satisfied that the current organisation of health care has given long life and low infant mortality at low cost. Even if it is accepted that low health care costs and good health prevail in Japan, slower economic growth rates, an ageing population and the development of new medical technologies will place increasing pressure on health care resources and will necessitate a more rational use of these resources. Good economic evaluation, by weighing benefits against costs, has an important role to play.<\/dc:description><dc:date>\n        2003<\/dc:date><dc:type>\n        Article<\/dc:type><dc:type>\n        PeerReviewed<\/dc:type><dc:format>\n        application\/pdf<\/dc:format><dc:language>\n        en<\/dc:language><dc:identifier>\n        http:\/\/eprints.lse.ac.uk\/160\/1\/Health_economic_evaluation_in_Japan.pdf<\/dc:identifier><dc:identifier>\n          Oliver, Adam  (2003) Health economic evaluation in Japan: a case study of one aspect of health technology assessment.  Health Policy, 63 (2).  pp. 197-204.  ISSN 0168-8510     <\/dc:identifier><dc:relation>\n        http:\/\/www.elsevier.com\/locate\/healthpol<\/dc:relation><dc:relation>\n        10.1016\/S0168-8510(02)00066-0<\/dc:relation><\/oai_dc:dc><\/metadata><\/record>","journals":null,"language":{"code":"en","id":9,"name":"English"},"relations":["http:\/\/eprints.lse.ac.uk\/160\/","http:\/\/www.elsevier.com\/locate\/healthpol","10.1016\/S0168-8510(02)00066-0"],"year":2003,"topics":["HB Economic Theory"],"subject":["Article","PeerReviewed"],"fullText":""}